Using Psychosocial Interventions and Medication-Assisted Treatment (MAT) to Improve the Efficacy (Effectiveness) of the Treatment for Opioid Use Disorder

Abstract

Medication-assisted treatment (MAT) with methadone, buprenorphine, and naltrexone is the evidence-based cornerstone of opioid use disorder (OUD) therapy. These medications reduce illicit opioid use, overdose risk, and OUD-related morbidity and mortality . Compared to counselling alone, MAT yields significantly higher retention in care and lower relapse rates. Clinical guidelines emphasize MAT (often called “MOUD”) as the primary intervention, with psychosocial therapies (e.g. cognitive-behavioural therapy, motivational interviewing, contingency management) as adjunctive supports.

Psychosocial interventions address cognitive-behavioural and motivational aspects of addiction. For example, contingency management (providing incentives for opioid-negative tests) significantly improves treatment engagement and retention when added to opioid agonist therapy. Integrating MAT with psychosocial support can enhance outcomes: sustained retention is linked to reduced drug use, improved social functioning, and higher quality of life. These combined treatments aim to support abstinence and recovery goals.

Evidence is mixed on some outcomes: meta-analyses generally find few differences in opioid abstinence between MAT alone and MAT plus general counselling. Significant implementation challenges remain, including underutilization of MAT (less than one-third of OUD patients receive any treatment), stigma, workforce shortages, and fragmented care (e.g. regulatory and funding barriers to psychosocial services). Comprehensive patient-centred care will require provider training, integrated services, and policies that expand access to and reimbursement for combined MAT–psychosocial programs. Guidelines also recommend integrating contingency management into MAT delivery to enhance retention.

These insights suggest that clinical programs should embed evidence-based counselling and incentive-based approaches within MAT to optimize retention, abstinence, and patient quality of life. Future research should identify the most effective medication-plus-psychosocial combinations and strategies to overcome access gaps, ultimately improving recovery and well-being for individuals with OUD.